About Us

About Us

Founded in 2020, AcadeMab Biomedical Inc. (hereinafter shortened as AM) is a start-up company dedicated to the development of new antibody drugs in the medical field that require urgent breakthroughs. As cancer is widely acknowledged as a leading cause of death across the globe, we take it upon ourselves to research on cancer therapy as our first step. From there, we expanded to other life-threaten diseases in different fields. To this end, we have developed multiple in-house technology platforms to break fresh ground for new antibody drugs. Our mission is to improve life quality and human health by providing the first-in-class or best-in-class new antibody drugs.

History

AcadeMab Biomedical Inc.’s story begins at the Institute of Cellular and Organismic Biology (ICOB), Academia Sinica where Dr. Han-Chung Wu works as a Distinguished Research Fellow. Dr. Wu has made significant breakthroughs that could lead to the much-anticipated ultimate cancer cure in animal models. His research findings on the epithelial cell adhesion molecule (EpCAM) antibody won him the Germination Program funding from Taiwan’s Ministry of Science and Technology (MOST) in November 2019. With MOST’s funding, Dr. Wu has embarked on the path of commercializing his antibody study results and founded AcadeMab Biomedical Inc. In 2020, AM set up a base at the National Biotechnology Research Park in Nangang.

 

About Us
Antibody <br> Development Platform

Antibody
Development Platform

Antibody <br> Deep Dive

Antibody
Deep Dive

mRNA <br> Development

mRNA
Development

Rock Solid Patent <br> Portfolio Strategy

Rock Solid Patent
Portfolio Strategy

Continue Promoting <br> Core Technologies

Continue Promoting
Core Technologies

AcadeMab History

AcadeMab has obtained exclusive licenses for key technologies from Academia Sinica, including antibody development and an mRNA vaccine development platform. AcadeMab strives to advance medical progress and offer innovative treatment options to meet the evolving needs of patients and the healthcare industry.
2024
Feb

A+ FastTrack Project Approved by DOIT

A+ FastTrack Project Approved by DOIT
2023
Sep

AcadeMab Biomedical and Academia Sinica enter into an exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids

AcadeMab Biomedical and Academia Sinica enter into an exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids
2023
Jan

AcadeMab receives US FDA and TFDA approval of AM-928 to initiate phase I clinical Trial for advanced solid tumors in Taiwan

AcadeMab receives US FDA and TFDA approval of AM-928 to initiate phase I clinical Trial for advanced solid tumors in Taiwan
2022
Aug

Approved as a biotech pharmaceutical industry by IDB, Taiwan

Approved as a biotech pharmaceutical industry by IDB, Taiwan
2020
Jun

AcadeMab Biomedical Inc. founded in 2020

 

 

 

AcadeMab Biomedical Inc. founded in 2020

BACK


Verification

Click the numbers in sequence.

academab.com may set and access academab.com cookies on your computer.  Cookies are used to provide our system with the basic information to provide the services you are requesting.  Cookies can be cleared at any time from your internet browser settings. 

 

Cookies Cookies

Privacy preference center

academab.com may set and access academab.com cookies on your computer.  Cookies are used to provide our system with the basic information to provide the services you are requesting.  Cookies can be cleared at any time from your internet browser settings. 

 

Privacy Privacy

Manage Consent Settings

Necessary Cookies

Enable All

網站運行離不開這些 Cookie 且您不能在系統中將其關閉。通常僅根據您所做出的操作(即服務請求)來設置這些 Cookie,如設置隱私偏好、登錄或填充表格。您可以將您的瀏覽器設置為阻止或向您提示這些 Cookie,但可能會導致某些網站功能無法工作。